Breakthrough clinical trials on EndoPAT®

  • Secondary prevention – in diagnosed or  symptomatic patients: 
    Patients who survived a heart attack Symptomatic patients – Stable
    anginaost-revascularization patients Heart failure patients –
    improving outcomes

    Leading researchers have concluded that targeting Endothelial function can improve outcomes way beyond conventional tests or risk measurement tools today.

    Both physicians and patients treat heart disease very seriously and treat symptoms aggressively.
    Yet, for patients who survived a heart attack the probability of sudden cardiac death is 4-6 times greater than that of the general population.

    With EndoPAT® direct feedback, your efforts at Secondary Prevention can be personalized and fine-tuned to help ensure they are as effective as possible. One size does not fit all.

    Symptomatic patients / Stable Angina
    Assessment of endothelial function by non-invasive PAT predicts late cardiovascular adverse events
    Rubinstein et al, Eu Heart Journal (2010)

    Method: 270 outpatients with unexplained chest pain (low-risk findings during stress testing and/or
    the absence of new obstructive lesions by an invasive coronary angiogram)
    The patients were followed for CV adverse events (AE): death, myocardial infarction, revascularization
    or cardiac hospitalization) during a 7-year follow-up
    Conclusion:  a low RH signal detected by EndoPAT®, consistent with endothelial dysfunction,
    was associated with higher AE (Adverse events) rate.
    L_RHI was an independent predictor of AE. Non-invasive assessment of peripheral vascular
    function may be useful for the identification of patients at risk for cardiac AEs.
    Takeaway: PAT signal can be a valuable tool in assessing CVD risk in patients with unexplained chest
    pain, allowing timely treatment and prevention of adverse events.


    Post-menopausal females with chest pain
    Digital Assessment of endothelial function and ischemic heart disease in women Matsuzawa et al, JACC 2010

    Method: 140 chest pain postmenopausal women tested with EndoPAT®, coronary angiography
    for obstructive CAD  and if non obstructive or normal angiography – then tested with Acetylcholine
    provocation test, adenosine reduced coronary flow reserve, and stress thallium test to further diagnose
    ischemic heart disease.
    Conclusion: PAT non-invasively predicted the presence of IHD, especially NOCAD (non-obstructive)
    which cannot be diagnosed by anatomical tests (angiography).
    PAT is a potentially useful clinical test and can effectively help to identify high-risk women with chest pain.

    Post-MI CAD patients*
    ndothelial dysfunction predicts residual risk in  coronary artery disease patients with statin therapy
    Matsue et al, EU Heart Journal abstract suppl. 2013
    Method: 213 CAD patients who were well treated with statin therapy (achieved LDL<100)
    Patients were followed-up for secondary CAE for a median of 2.7 years.
    During follow-up, CAE occurred in 6 (5.5%) patients in the L_RHI > 0.52 group and 16 (15.5%) patients in
    the L_RHI <0.52 group (P=0.023).
    Conclusions: L_RHI (Endoscore) was an independent predictor for CAE (coronary artery events) even after
    adjusting by Framingham traditional risk factors for secondary CAE
    Takeaway: EndoPAT® must be used to follow up on cad patients and target endothelial function to improve prognosis.

    Heart Failure patients
    Akiyama et al, JACC, Journal of American College of Cardiology, 2012
    Method: 321 patients with heart failure  tested with EndoPAT®.
    Rate of adverse events was almost 4 times in the group of endothelial dysfunction (28.1%) vs.
    8.8% in the normal function group. Patients followed up for a mean of 20 months
    Unique EndoPAT® value: Peripheral endothelial dysfunction independently correlated with future
    cardiovascular events, adding incremental clinical significance for risk stratification in patients with HF.

  • Drop us a note
    * indicates required field